Susquehanna International Group
ALDX icon

Susquehanna International Group’s Aldeyra Therapeutics ALDX Stock Holding History

Susquehanna International Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$395K Buy
234,000
+191,900
+456% +$841K ﹤0.01% 10249
2025
Q4 		$218K Buy
+42,100
New +$216K ﹤0.01% 10694
2025
Q3 		– Sell
-16,600
Closed -$63.6K – 12272
2025
Q2 		$63.6K Sell
16,600
-21,400
-56% -$55.3K ﹤0.01% 12035
2025
Q1 		$219K Sell
38,000
-1,700
-4% -$10K ﹤0.01% 10764
2024
Q4 		$198K Buy
39,700
+1,800
+5% +$9.24K ﹤0.01% 10736
2024
Q3 		$204K Buy
37,900
+21,500
+131% +$102K ﹤0.01% 10432
2024
Q2 		$54.3K Buy
16,400
+3,100
+23% +$12.1K ﹤0.01% 11375
2024
Q1 		$43.5K Sell
13,300
-29,100
-69% -$95.7K ﹤0.01% 11608
2023
Q4 		$149K Sell
42,400
-54,800
-56% -$169K ﹤0.01% 10985
2023
Q3 		$649K Sell
97,200
-54,200
-36% -$402K ﹤0.01% 7617
2023
Q2 		$1.27M Buy
151,400
+91,700
+154% +$903K ﹤0.01% 6140
2023
Q1 		$593K Buy
59,700
+8,700
+17% +$61.5K ﹤0.01% 8155
2022
Q4 		$355K Sell
51,000
-40,800
-44% -$233K ﹤0.01% 8690
2022
Q3 		$490K Buy
91,800
+45,700
+99% +$274K ﹤0.01% 8544
2022
Q2 		$184K Sell
46,100
-183,200
-80% -$630K ﹤0.01% 10754
2022
Q1 		$1.02M Buy
229,300
+113,700
+98% +$453K ﹤0.01% 7063
2021
Q4 		$462K Buy
115,600
+69,600
+151% +$531K ﹤0.01% 9414
2021
Q3 		$404K Sell
46,000
-95,100
-67% -$873K ﹤0.01% 9915
2021
Q2 		$1.6M Sell
141,100
-77,700
-36% -$934K ﹤0.01% 6470
2021
Q1 		$2.6M Buy
218,800
+127,300
+139% +$1.47M ﹤0.01% 5294
2020
Q4 		$628K Buy
91,500
+56,200
+159% +$395K ﹤0.01% 7783
2020
Q3 		$262K Buy
35,300
+22,200
+169% +$143K ﹤0.01% 8972
2020
Q2 		$55K Buy
13,100
+1,500
+13% +$5.48K ﹤0.01% 9722
2020
Q1 		$29K Sell
11,600
-48,700
-81% -$219K ﹤0.01% 9831
2019
Q4 		$350K Buy
60,300
+40,200
+200% +$232K ﹤0.01% 7704
2019
Q3 		$106K Sell
20,100
-9,900
-33% -$53.3K ﹤0.01% 9534
2019
Q2 		$180K Sell
30,000
-97,700
-77% -$735K ﹤0.01% 9219
2019
Q1 		$1.15M Buy
127,700
+117,300
+1,128% +$997K ﹤0.01% 4763
2018
Q4 		$86K Sell
10,400
-14,800
-59% -$152K ﹤0.01% 8283
2018
Q3 		$348K Buy
+25,200
New +$204K ﹤0.01% 7182

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group's ALDX Position: Q1 2026 in Review

Susquehanna International Group increased its Aldeyra Therapeutics (ALDX) stake by 343% in Q1 2026, buying an estimated $944K and bringing the position to 278,442 shares worth $471K. The position accounts for ﹤0.01% of the portfolio, ranked #9835.

Susquehanna International Group first reported a position in ALDX in Q1 2018 and has held it in 32 quarters since. The position peaked at $10.9M in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Susquehanna International Group held 278,442 shares of Aldeyra Therapeutics worth $471K as of Q1 2026.
  • Susquehanna International Group bought 215,535 Aldeyra Therapeutics shares in Q1 2026, an estimated $944K.
  • Aldeyra Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #9835 holding.
  • Susquehanna International Group first reported a position in Aldeyra Therapeutics in Q1 2018 and has held it in 32 quarters since.
  • Susquehanna International Group's Aldeyra Therapeutics position peaked at $10.9M in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.